Edgewise reports loss as it continues trials
Edgewise Therapeutics Inc. (Nasdaq: EWTX), a Boulder-based muscle disease biopharmaceutical company, has reported a net loss for the fourth quarter of 2023, which ended Dec. 31, 2023.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
